South Korea’s financial markets showcased a mixed performance with the KOSPI index regaining strength, while tech giant Samsung Electronics stumbled to a new low for the year.
The KOSPI index closed at 2604.92 points, marking an ascend by 11.1 points or a 0.43% increase, as institutional and foreign investors exhibited a buying spree that propelled the index past the significant 2,600 level. The lift came amid a broader uptick in Asian markets, instilling a renewed sense of confidence among traders.
In contrast, Samsung Electronics, a bellwether for the tech sector and a heavyweight in the index, saw its stock price retreat by 200 won to 59,000 won at the close, after hitting new 52 week lows of 58,500. This downturn of 0.34% was enough to register a new yearly low for the stock, reflecting investor concerns that has seen Samsung drop 25.88% in value through the year so far.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
The index’s next highest weighted component, SK Hynix ended the day in contrasting fashion to Samsung. The next Korean listed tech behemoth, bucked the trend and added 1.92% to close out at 190,900 won. This rebound for SK Hynix is significant as it exemplifies the sector’s volatility and the investor’s appetite for semiconductor stocks and put’s the stock near the mid-point of it’s 52 week range.
The tech-centric KOSDAQ index also ended on a higher note, advancing by 6.73 points or 0.89%, finishing at 759.95. Foreign investors played a substantial role here, with net purchases amounting to 1517 billion won, affirming their bullish stance on Korea’s growth prospects and innovation potential.
Biopharmaceutical firm Ligacube Bio also stood in the limelight with a robust 5.49% increase in its stock price, ending at 130,700 won. The catalyst for this upward movement was the announcement of the commencement of phase 1 clinical trials for their ADC candidate ‘LCB97’, spotlighting the potential upside in biotech investments.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
